Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies

Ophira M. Ginsburg, MSc, MD, FRCPC
Published: Thursday, Oct 12, 2017



Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.

Women in families with MSH2 germline mutation for Lynch syndrome need to be counseled, especially if they test positive for the mutation, states Ginsburg. These women have a very high risk of uterine cancer and endometrial cancer. Additionally, the risk of uterine cancer in those families is higher than the risk of ovarian cancer.

As there is no proven way to screen for uterine cancer, there is a suggestion that random sampling of the endometrium may have some value. Uterine cancer can also be associated with PTEN mutation, which has risks of breast, uterine, and other cancers. This is an emerging area of gynecologic oncologic genetics, explains Ginsburg.



Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.

Women in families with MSH2 germline mutation for Lynch syndrome need to be counseled, especially if they test positive for the mutation, states Ginsburg. These women have a very high risk of uterine cancer and endometrial cancer. Additionally, the risk of uterine cancer in those families is higher than the risk of ovarian cancer.

As there is no proven way to screen for uterine cancer, there is a suggestion that random sampling of the endometrium may have some value. Uterine cancer can also be associated with PTEN mutation, which has risks of breast, uterine, and other cancers. This is an emerging area of gynecologic oncologic genetics, explains Ginsburg.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x